Sompraz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

# Sompraz HP (Pantoprazole) ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion. ## Primary Indications * Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis. * Zollinger-Ellison syndrome. * Part of *Helicobacter pylori* eradication regimens. ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks. For maintenance therapy, 40 mg once daily. In severe cases, may increase to 40 mg twice daily. * **Zollinger-Ellison Syndrome:** Starting dose is typically 40 mg orally twice daily. Doses may be titrated as needed; maximum dose is 80 mg orally twice daily. * ***H. pylori* Eradication:** Part of a triple therapy regimen: Pantoprazole 40 mg orally twice daily, plus clarithromycin 500 mg orally twice daily, and amoxicillin 1000 mg orally twice daily, or metronidazole 500 mg orally twice daily, for 7-14 days. ## Pediatric Dosing * **GERD/Erosive Esophagitis:** * **12 years and older:** 40 mg orally once daily for up to 8 weeks. * **1 to <12 years:** 20 mg orally once daily for up to 8 weeks. Doses higher than 20 mg daily have not been studied in this age group. ## Dose Adjustments * **Hepatic Impairment:** Maximum dose is 20 mg orally once daily. * **Renal Impairment:** No dose adjustment necessary. ## Contraindications * Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles. ## Adverse Effects * Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness. * Long-term use: Increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, hypomagnesemia. ## Key Drug Interactions * **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, erlotinib, mycophenolate mofetil. * Pantoprazole increases gastric pH, decreasing absorption. Separate administration or consider alternative. * **Methotrexate:** PPIs may increase methotrexate levels. * **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel (consider alternative). * **CYP3A4 substrates:** Caution when co-administered with drugs that are metabolized by CYP3A4. ## Monitoring * Monitor for signs and symptoms of *Clostridium difficile* infection. * Monitor serum magnesium levels, especially with long-term use (e.g., >1 year) or concomitant use of other medications that lower magnesium (e.g., diuretics, digoxin). * Consider monitoring vitamin B12 levels with prolonged therapy. * Assess for bone fracture risk in patients with risk factors. ## Clinical Pearls * Pantoprazole can be taken with or without food. * For patients unable to swallow whole tablets, pantoprazole for oral suspension can be used. Delayed-release tablets should not be crushed or chewed. * The risk of adverse events, particularly bone fractures and *C. difficile* infection, increases with duration of therapy. Use the lowest effective dose for the shortest duration necessary. * Long-term PPI use should be regularly re-evaluated. *** This information is intended for healthcare professionals. Always consult the official prescribing information and relevant literature before making clinical decisions.